ID	Gene Name	Species	BIOCARTA	GOTERM_BP_DIRECT	GOTERM_CC_DIRECT	GOTERM_MF_DIRECT	INTERPRO	KEGG_PATHWAY	OMIM_DISEASE	SMART	UP_KW_BIOLOGICAL_PROCESS	UP_KW_CELLULAR_COMPONENT	UP_KW_DISEASE	UP_KW_DOMAIN	UP_KW_LIGAND	UP_KW_MOLECULAR_FUNCTION	UP_KW_PTM	UP_SEQ_FEATURE
EBNA1BP2	EBNA1 binding protein 2(EBNA1BP2)	Homo sapiens		GO:0006364~rRNA processing,GO:0042273~ribosomal large subunit biogenesis,	GO:0005694~chromosome,GO:0005730~nucleolus,GO:0030687~preribosome, large subunit precursor,GO:0034399~nuclear periphery,	GO:0003723~RNA binding,GO:0005515~protein binding,	IPR008610:Ebp2,				KW-0690~Ribosome biogenesis,	KW-0539~Nucleus,		KW-0175~Coiled coil,			KW-0007~Acetylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	COMPBIAS:Basic and acidic residues,COMPBIAS:Basic residues,CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),REGION:Disordered,
ELAVL1	ELAV like RNA binding protein 1(ELAVL1)	Homo sapiens	h_vegfPathway:VEGF, Hypoxia, and Angiogenesis,	GO:0006606~protein import into nucleus,GO:0016441~post-transcriptional gene silencing,GO:0032930~positive regulation of superoxide anion generation,GO:0045727~positive regulation of translation,GO:0048255~mRNA stabilization,GO:0051260~protein homooligomerization,GO:0060965~negative regulation of miRNA-mediated gene silencing,GO:0061157~mRNA destabilization,GO:0070935~3'-UTR-mediated mRNA stabilization,GO:2000036~regulation of stem cell population maintenance,	GO:0000932~P-body,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005737~cytoplasm,GO:0005783~endoplasmic reticulum,GO:0005829~cytosol,GO:0010494~cytoplasmic stress granule,GO:0016020~membrane,GO:0016528~sarcoplasm,GO:0031410~cytoplasmic vesicle,GO:0098794~postsynapse,GO:0098978~glutamatergic synapse,GO:1990904~ribonucleoprotein complex,	GO:0003723~RNA binding,GO:0003725~double-stranded RNA binding,GO:0003729~mRNA binding,GO:0003730~mRNA 3'-UTR binding,GO:0005515~protein binding,GO:0019901~protein kinase binding,GO:0035198~miRNA binding,GO:0035925~mRNA 3'-UTR AU-rich region binding,GO:0042803~protein homodimerization activity,GO:0106222~lncRNA binding,	IPR000504:RRM_dom,IPR002343:Hud_Sxl_RNA,IPR006548:ELAD_HU_SF,IPR012677:Nucleotide-bd_a/b_plait_sf,IPR034996:HuR_RRM2,IPR035979:RBD_domain_sf,	hsa04152:AMPK signaling pathway,hsa04657:IL-17 signaling pathway,		SM00360:RRM,		KW-0539~Nucleus,KW-0963~Cytoplasm,		KW-0677~Repeat,		KW-0694~RNA-binding,	KW-0007~Acetylation,KW-0488~Methylation,KW-0597~Phosphoprotein,KW-0832~Ubl conjugation,KW-1017~Isopeptide bond,	CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2),DOMAIN:RRM,DOMAIN:RRM 1,DOMAIN:RRM 2,DOMAIN:RRM 3,MUTAGEN:S->A: Decreases phosphorylation by PRKCD.,MUTAGEN:S->A: Decreases phosphorylation by PRKCD. Nearly abolishes phosphorylation by PRKCD and translocation from the nucleus into the cytoplasm; when associated with A-221.,MUTAGEN:S->A: Decreases phosphorylation by PRKCD. Nearly abolishes phosphorylation by PRKCD and translocation from the nucleus into the cytoplasm; when associated with A-318.,REGION:Disordered,
MOB2	MOB kinase activator 2(MOB2)	Homo sapiens		GO:0001934~positive regulation of protein phosphorylation,GO:0007165~signal transduction,GO:0016310~phosphorylation,	GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005730~nucleolus,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0048471~perinuclear region of cytoplasm,	GO:0005515~protein binding,GO:0016301~kinase activity,GO:0030295~protein kinase activator activity,GO:0046872~metal ion binding,	IPR005301:MOB_kinase_act_fam,IPR036703:MOB_kinase_act_sf,			SM01388:Mob1_phocein,		KW-0539~Nucleus,KW-0963~Cytoplasm,			KW-0479~Metal-binding,KW-0862~Zinc,	KW-0418~Kinase,KW-0808~Transferase,	KW-0597~Phosphoprotein,	REGION:Disordered,
NDUFB4	NADH:ubiquinone oxidoreductase subunit B4(NDUFB4)	Homo sapiens		GO:0006120~mitochondrial electron transport, NADH to ubiquinone,GO:0006979~response to oxidative stress,GO:0009060~aerobic respiration,GO:0032981~mitochondrial respiratory chain complex I assembly,GO:0042776~proton motive force-driven mitochondrial ATP synthesis,GO:0055085~transmembrane transport,	GO:0005654~nucleoplasm,GO:0005739~mitochondrion,GO:0005743~mitochondrial inner membrane,	GO:0008137~NADH dehydrogenase (ubiquinone) activity,	IPR009866:NADH_UbQ_OxRdtase_NDUFB4_su,	hsa00190:Oxidative phosphorylation,hsa01100:Metabolic pathways,hsa04714:Thermogenesis,hsa04723:Retrograde endocannabinoid signaling,hsa04932:Non-alcoholic fatty liver disease,hsa05010:Alzheimer disease,hsa05012:Parkinson disease,hsa05014:Amyotrophic lateral sclerosis,hsa05016:Huntington disease,hsa05020:Prion disease,hsa05022:Pathways of neurodegeneration - multiple diseases,hsa05208:Chemical carcinogenesis - reactive oxygen species,hsa05415:Diabetic cardiomyopathy,			KW-0249~Electron transport,KW-0679~Respiratory chain,KW-0813~Transport,	KW-0472~Membrane,KW-0496~Mitochondrion,KW-0999~Mitochondrion inner membrane,		KW-0812~Transmembrane,KW-1133~Transmembrane helix,			KW-0007~Acetylation,KW-0597~Phosphoprotein,	TRANSMEM:Helical,
AGRN	agrin(AGRN)	Homo sapiens	h_agrPathway:Agrin in Postsynaptic Differentiation,	GO:0007010~cytoskeleton organization,GO:0007165~signal transduction,GO:0007213~G protein-coupled acetylcholine receptor signaling pathway,GO:0007268~chemical synaptic transmission,GO:0007528~neuromuscular junction development,GO:0030154~cell differentiation,GO:0043113~receptor clustering,GO:0043547~positive regulation of GTPase activity,GO:0045162~clustering of voltage-gated sodium channels,GO:0045887~positive regulation of synaptic assembly at neuromuscular junction,GO:0045944~positive regulation of transcription by RNA polymerase II,GO:0050808~synapse organization,GO:0051491~positive regulation of filopodium assembly,	GO:0005576~extracellular region,GO:0005604~basement membrane,GO:0005796~Golgi lumen,GO:0005886~plasma membrane,GO:0016020~membrane,GO:0043202~lysosomal lumen,GO:0045202~synapse,GO:0062023~collagen-containing extracellular matrix,GO:0070062~extracellular exosome,	GO:0002162~dystroglycan binding,GO:0005200~structural constituent of cytoskeleton,GO:0005201~extracellular matrix structural constituent,GO:0005509~calcium ion binding,GO:0005515~protein binding,GO:0033691~sialic acid binding,GO:0035374~chondroitin sulfate binding,GO:0043236~laminin binding,GO:0043395~heparan sulfate proteoglycan binding,	IPR000082:SEA_dom,IPR000742:EGF-like_dom,IPR001791:Laminin_G,IPR001881:EGF-like_Ca-bd_dom,IPR002049:LE_dom,IPR002350:Kazal_dom,IPR003645:Fol_N,IPR003884:FacI_MAC,IPR004850:NtA_dom,IPR008993:TIMP-like_OB-fold,IPR013320:ConA-like_dom_sf,IPR036058:Kazal_dom_sf,IPR036364:SEA_dom_sf,	hsa04512:ECM-receptor interaction,hsa04820:Cytoskeleton in muscle cells,	615120~Myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects,	SM00057:FIMAC,SM00179:EGF_CA,SM00180:EGF_Lam,SM00181:EGF,SM00200:SEA,SM00274:FOLN,SM00280:KAZAL,SM00282:LamG,	KW-0221~Differentiation,	KW-0272~Extracellular matrix,KW-0472~Membrane,KW-0770~Synapse,KW-0964~Secreted,KW-1003~Cell membrane,	KW-0225~Disease variant,KW-1004~Congenital myasthenic syndrome,	KW-0245~EGF-like domain,KW-0424~Laminin EGF-like domain,KW-0677~Repeat,KW-0732~Signal,KW-0812~Transmembrane,KW-1133~Transmembrane helix,	KW-0106~Calcium,KW-0479~Metal-binding,	KW-0217~Developmental protein,KW-9996~Developmental protein,	KW-0325~Glycoprotein,KW-0357~Heparan sulfate,KW-0597~Phosphoprotein,KW-0654~Proteoglycan,KW-1015~Disulfide bond,	CARBOHYD:N-linked (GlcNAc...) asparagine,CARBOHYD:O-linked (Fuc...) serine,COMPBIAS:Polar residues,COMPBIAS:Pro residues,DISULFID:Or C-152 with C-183,DOMAIN:EGF-like,DOMAIN:EGF-like 1,DOMAIN:EGF-like 2,DOMAIN:EGF-like 3,DOMAIN:EGF-like 4,DOMAIN:Kazal-like,DOMAIN:Kazal-like 1,DOMAIN:Kazal-like 2,DOMAIN:Kazal-like 3,DOMAIN:Kazal-like 4,DOMAIN:Kazal-like 5,DOMAIN:Kazal-like 6,DOMAIN:Kazal-like 7,DOMAIN:Kazal-like 8,DOMAIN:Kazal-like 9,DOMAIN:Laminin EGF-like,DOMAIN:Laminin EGF-like 1,DOMAIN:Laminin EGF-like 2,DOMAIN:Laminin G,DOMAIN:Laminin G-like 1,DOMAIN:Laminin G-like 2,DOMAIN:Laminin G-like 3,DOMAIN:NtA,DOMAIN:SEA,REGION:Disordered,SITE:Alternative splice site to produce 'x' isoforms,SITE:Alternative splice site to produce 'y' isoforms,SITE:Alternative splice site to produce 'z' isoforms,SITE:Cleavage, alpha site; by neurotrypsin,SITE:Cleavage, beta site; by neurotrypsin,SITE:Critical for cleavage by neurotrypsin,SITE:Highly important for the agrin receptor complex activity of the 'z(8)' insert,TRANSMEM:Helical,
AHR	aryl hydrocarbon receptor(AHR)	Homo sapiens	h_acrPathway:Ahr Signal Transduction Pathway,	GO:0001568~blood vessel development,GO:0002819~regulation of adaptive immune response,GO:0002841~negative regulation of T cell mediated immune response to tumor cell,GO:0006355~regulation of DNA-templated transcription,GO:0006357~regulation of transcription by RNA polymerase II,GO:0006805~xenobiotic metabolic process,GO:0006915~apoptotic process,GO:0007049~cell cycle,GO:0009410~response to xenobiotic stimulus,GO:0009636~response to toxic substance,GO:0010468~regulation of gene expression,GO:0019933~cAMP-mediated signaling,GO:0030522~intracellular receptor signaling pathway,GO:0030888~regulation of B cell proliferation,GO:0032922~circadian regulation of gene expression,GO:0045892~negative regulation of DNA-templated transcription,GO:0045893~positive regulation of DNA-templated transcription,GO:0045944~positive regulation of transcription by RNA polymerase II,GO:0048511~rhythmic process,GO:0050728~negative regulation of inflammatory response,GO:0071219~cellular response to molecule of bacterial origin,GO:0071320~cellular response to cAMP,GO:1904322~cellular response to forskolin,GO:1904613~cellular response to 2,3,7,8-tetrachlorodibenzodioxine,	GO:0000785~chromatin,GO:0005634~nucleus,GO:0005654~nucleoplasm,GO:0005667~transcription regulator complex,GO:0005737~cytoplasm,GO:0005829~cytosol,GO:0032991~protein-containing complex,GO:0034751~aryl hydrocarbon receptor complex,GO:0034752~cytosolic aryl hydrocarbon receptor complex,GO:0034753~nuclear aryl hydrocarbon receptor complex,	GO:0000976~transcription cis-regulatory region binding,GO:0000981~DNA-binding transcription factor activity, RNA polymerase II-specific,GO:0000987~cis-regulatory region sequence-specific DNA binding,GO:0001094~TFIID-class transcription factor complex binding,GO:0001223~transcription coactivator binding,GO:0003677~DNA binding,GO:0003700~DNA-binding transcription factor activity,GO:0004879~nuclear receptor activity,GO:0005515~protein binding,GO:0017025~TBP-class protein binding,GO:0042803~protein homodimerization activity,GO:0046982~protein heterodimerization activity,GO:0046983~protein dimerization activity,GO:0051879~Hsp90 protein binding,GO:0061629~RNA polymerase II-specific DNA-binding transcription factor binding,GO:0070888~E-box binding,GO:1990837~sequence-specific double-stranded DNA binding,	IPR000014:PAS,IPR001610:PAC,IPR011598:bHLH_dom,IPR013655:PAS_fold_3,IPR013767:PAS_fold,IPR033348:AHR_bHLH,IPR035965:PAS-like_dom_sf,IPR036638:HLH_DNA-bd_sf,IPR039091:AHR/AHRR,	hsa04659:Th17 cell differentiation,hsa04934:Cushing syndrome,hsa05207:Chemical carcinogenesis - receptor activation,hsa05208:Chemical carcinogenesis - reactive oxygen species,	618345~Retinitis pigmentosa 85,	SM00086:PAC,SM00091:PAS,SM00353:HLH,	KW-0090~Biological rhythms,KW-0131~Cell cycle,KW-0804~Transcription,KW-0805~Transcription regulation,	KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0682~Retinitis pigmentosa,	KW-0677~Repeat,		KW-0010~Activator,KW-0238~DNA-binding,KW-0675~Receptor,KW-0678~Repressor,	KW-0007~Acetylation,KW-0013~ADP-ribosylation,	COMPBIAS:Polar residues,DOMAIN:BHLH,DOMAIN:PAC,DOMAIN:PAS,DOMAIN:PAS 1,DOMAIN:PAS 2,DOMAIN:bHLH,MOTIF:Nuclear export signal,MOTIF:Nuclear localization signal 1,MOTIF:Nuclear localization signal 2,MUTAGEN:A->D: Abolishes transcription factor activity; when associated with D-50 and D-82.,MUTAGEN:F->D: Abolishes transcription factor activity; when associated with D-50 and D-79.,MUTAGEN:F->D: Interferes with transcription factor activity.,MUTAGEN:H->G: Almost abolishes transcription factor activity. No effect on nuclear translocation upon ligand binding.,MUTAGEN:I->D: Interferes with transcription factor activity.,MUTAGEN:L->D: Abolishes transcription factor activity; when associated with D-79 and D-82.,MUTAGEN:L->D: Interferes with transcription factor activity.,MUTAGEN:LLQAL->ELQDE: Strongly reduces transcription factor activity.,MUTAGEN:R->D: Abolishes transcription factor activity. Alters on nuclear translocation upon ligand binding.,MUTAGEN:S->G: Strongly reduces transcription factor activity.,MUTAGEN:V->A: Increases specific ligand binding.,MUTAGEN:V->D: Abolishes specific ligand binding.,MUTAGEN:V->D: Interferes with transcription factor activity.,MUTAGEN:V->L,G: No effect on specific ligand binding.,REGION:DNA-binding,REGION:Disordered,REGION:Required for maintaining the overall integrity of the AHR:ARNT heterodimer and its transcriptional activity,
MECR	mitochondrial trans-2-enoyl-CoA reductase(MECR)	Homo sapiens		GO:0006631~fatty acid metabolic process,GO:0006633~fatty acid biosynthetic process,	GO:0005634~nucleus,GO:0005739~mitochondrion,GO:0005759~mitochondrial matrix,	GO:0016631~enoyl-[acyl-carrier-protein] reductase activity (NAD(P)H),GO:0019166~trans-2-enoyl-CoA reductase (NADPH) activity,GO:0141148~enoyl-[acyl-carrier-protein] reductase (NADPH) activity,	IPR011032:GroES-like_sf,IPR013149:ADH-like_C,IPR013154:ADH-like_N,IPR020843:PKS_ER,IPR036291:NAD(P)-bd_dom_sf,	hsa00061:Fatty acid biosynthesis,hsa00062:Fatty acid elongation,hsa01100:Metabolic pathways,hsa01212:Fatty acid metabolism,	617282~Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities,620629~Optic atrophy 16,	SM00829:PKS_ER,	KW-0275~Fatty acid biosynthesis,KW-0276~Fatty acid metabolism,KW-0443~Lipid metabolism,KW-0444~Lipid biosynthesis,	KW-0496~Mitochondrion,KW-0539~Nucleus,KW-0963~Cytoplasm,	KW-0225~Disease variant,KW-1023~Dystonia,	KW-0809~Transit peptide,	KW-0521~NADP,	KW-0560~Oxidoreductase,	KW-0007~Acetylation,	ACT_SITE:Proton donor,DOMAIN:Alcohol dehydrogenase-like C-terminal,DOMAIN:Enoyl reductase (ER),MUTAGEN:F->Y: Strongly increases activity with trans-oct-2-enoyl-CoA. Decreases activity with trans-tetradec-2-enoyl-CoA by 25%. Decreases activity with trans-hexadec-2-enoyl-CoA by 68%.,MUTAGEN:G->S: Strongly increases activity with trans-oct-2-enoyl-CoA. Decreases activity with trans-tetradec-2-enoyl-CoA by 73%. Decreases activity with trans-hexadec-2-enoyl-CoA by 80%.,MUTAGEN:I->M: Strongly increases activity with trans-oct-2-enoyl-CoA. No effect on activity with trans-tetradec-2-enoyl-CoA. Decreases activity with trans-hexadec-2-enoyl-CoA by 20%.,MUTAGEN:S->A: Reduces catalytic activity by 68%.,MUTAGEN:T->A: Reduces catalytic activity by 69%.,MUTAGEN:W->A: Reduces catalytic activity by 98%. Strongly reduces affinity for trans-oct-2-enoyl-CoA.,MUTAGEN:W->L: Reduces catalytic activity by 87%. Strongly reduces affinity for trans-oct-2-enoyl-CoA.,MUTAGEN:Y->F: Reduces catalytic activity by 95%. Strongly reduces affinity for trans-oct-2-enoyl-CoA.,TRANSIT:Mitochondrion,
UBE2H	ubiquitin conjugating enzyme E2 H(UBE2H)	Homo sapiens		GO:0000209~protein polyubiquitination,GO:0006511~ubiquitin-dependent protein catabolic process,GO:0032446~protein modification by small protein conjugation,GO:0043161~proteasome-mediated ubiquitin-dependent protein catabolic process,GO:0070936~protein K48-linked ubiquitination,GO:0070979~protein K11-linked ubiquitination,	GO:0005634~nucleus,GO:0005829~cytosol,	GO:0004842~ubiquitin-protein transferase activity,GO:0005515~protein binding,GO:0005524~ATP binding,GO:0019787~ubiquitin-like protein transferase activity,GO:0061631~ubiquitin conjugating enzyme activity,	IPR000608:UBQ-conjugat_E2,IPR016135:UBQ-conjugating_enzyme/RWD,IPR023313:UBQ-conjugating_AS,	hsa04120:Ubiquitin mediated proteolysis,		SM00212:UBCc,	KW-0833~Ubl conjugation pathway,				KW-0067~ATP-binding,KW-0547~Nucleotide-binding,	KW-0808~Transferase,	KW-0007~Acetylation,KW-0832~Ubl conjugation,	ACT_SITE:Glycyl thioester intermediate,DOMAIN:UBC core,REGION:Disordered,
